Welcome to our dedicated page for Kyverna Therapeutics SEC filings (Ticker: KYTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kyverna Therapeutics filings document a late-stage clinical biopharmaceutical company developing cell therapies for autoimmune diseases. Its Form 8-K disclosures frequently cover Regulation FD updates for miv-cel clinical data, business and financial results, and material corporate events involving leadership, board composition, and commercial organization changes.
The company's proxy and governance filings describe director elections, board committees, executive compensation, stockholder voting matters, and equity incentive arrangements, including inducement awards. SEC records also identify Kyverna's Nasdaq-listed common stock and provide formal disclosure around its CAR T development strategy, clinical programs in neuroimmunology, capital planning, risk factors, and public-company governance.